The invention provides a photodynamic therapy-based method for treating ocular glaucoma. A photosensitizer, for example, a benzoporphyrin derivative photosensitizer, is administered to a mammal either having or at risk of developing ocular glaucoma. The photosensitizer, when present in the ciliary body, is activated by light, for example, light from a laser. The treatment results in a reduction of intraocular pressure within the treated eye, which can persist for a prolonged period of time.

Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.

The present invention relates to a use of alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis. The use is suitable for various type of psoriasis by utilizing photodynamic therapy. The photosensitizer is used to treat psoriasis by utilizing laser wave length of 670 nm, with high light sensitivity, fast photobleaching, short time needed in protection from light, and avoiding potential toxic and side-effect of photochemistry therapy by using ultraviolet irradiation. The preparation used in the use of -(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis includes solution, cream, nanomicelle, microsphere etc, and mode of administration can be systemic or topical administration. The practicability of treating psoriasis by photodynamic therapy has been validated on cell and animal model. The use achieves perfect effect.

The present invention relates to a medicinal material for light therapy, comprising a matrix material and a photosensitizer, wherein the photosensitizer is dispersed inside the matrix material by copolymerization, is mixed inside the matrix material, or attached to the surface of the matrix material by surface grafting, modification, coating and the like. The present material can kill diseased tissue cells with a radiation under selected wavelength so as to obtain a phototherapy treatment of ophthalmic diseases. The present invention also provides a process for preparing the material and a use in preparing an ophthalmic medical device.

The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitizing agent, and uses thereof in photochemical internalization (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.

The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.

The present disclosure provides a degradable near-infrared photosensitizer, a preparation method, and an application thereof, and relates to the technical field of photosensitizer. The degradable near-infrared photosensitizer may be any one of a porphyrin compound, and a pharmaceutically acceptable salt, a solvate, a non-covalent bonded composite, a complex, and a prodrug of the porphyrin compound, and a structure of the porphyrin compound may be as shown in formula 1: The present disclosure further provides a preparation method for the degradable near-infrared photosensitizer and an application of the degradable near-infrared photosensitizer. The degradable near-infrared photosensitizer provided by the present disclosure may be degraded while generating reactive oxygen species during irradiation, and when the irradiation is ended, the photosensitizer may be completely converted into a low-toxicity substance that does not have the photoactivity such that effectively solves a problem of a residue of the photosensitizer in the prior art.

##STR00001##

The present invention relates to a use of alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis. The use is suitable for various type of psoriasis by utilizing photodynamic therapy. The photosensitizer is used to treat psoriasis by utilizing laser wave length of 670 nm, with high light sensitivity, fast photobleaching, short time needed in protection from light, and avoiding potential toxic and side-effect of photochemistry therapy by using ultraviolet irradiation. The preparation used in the use of -(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis includes solution, cream, nanomicelle, microsphere etc, and mode of administration can be systemic or topical administration. The practicability of treating psoriasis by photodynamic therapy has been validated on cell and animal model. The use achieves perfect effect.

The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<>, COS<>, SO3<>, PO3<2>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.